Needham Reiterates Buy on Pliant Therapeutics, Maintains $38 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Joseph Stringer has reiterated a Buy rating on Pliant Therapeutics (NASDAQ:PLRX) and maintained a $38 price target.
May 07, 2024 | 11:54 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Joseph Stringer reiterates a Buy rating on Pliant Therapeutics with a maintained $38 price target.
The reiteration of a Buy rating and maintenance of a $38 price target by a reputable analyst suggests a strong vote of confidence in Pliant Therapeutics' potential. This endorsement is likely to positively influence investor sentiment and could lead to a short-term uptick in PLRX's stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100